|
1
|
Yang Q, Ye H, Sun G, Wang K, Dai L, Qiu C, Shi J, Zhu J, Wang X, Wang P. Human Proteome Microarray identifies autoantibodies to tumor-associated antigens as serological biomarkers for the diagnosis of hepatocellular carcinoma. Mol Oncol 2023; 17:887-900. [PMID: 36587394 PMCID: PMC10158779 DOI: 10.1002/1878-0261.13371] [Citation(s) in RCA: 3] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/13/2022] [Revised: 11/14/2022] [Accepted: 12/30/2022] [Indexed: 01/02/2023] Open
Abstract
The identification of the high-efficiency and non-invasive biomarkers for hepatocellular carcinoma (HCC) detection is urgently needed. This study aims to screen out potential autoantibodies to tumor-associated antigens (TAAbs) and to assess their diagnostic value for HCC. Fifteen potential TAAbs were screened out from the Human Proteome Microarray by 30 HCC sera and 22 normal control sera, of which eight passed multiple-stage validations by ELISA with a total of 1625 human serum samples from normal controls (NCs) and patients with HCC, liver cirrhosis, chronic hepatitis B, gastric cancer, esophageal cancer, and colorectal cancer. Finally, an immunodiagnostic model including six TAAbs (RAD23A, CAST, RUNX1T1, PAIP1, SARS, PRKCZ) was constructed by logistic regression, and yielded the area under curve (AUC) of 0.835 and 0.788 in training and validation sets, respectively. The serial serum samples from HCC model mice were tested to explore the change in TAAbs during HCC formation, and an increasing level of autoantibodies was observed. In conclusion, the panel of six TAAbs can provide potential value for HCC detection, and the strategy to identify novel serological biomarkers can also provide new clues in understanding immunodiagnostic biomarkers.
Collapse
Affiliation(s)
- Qian Yang
- The State Key Laboratory of Esophageal Cancer Prevention & Treatment, Zhengzhou University, China.,Department of Prenatal Diagnosis Center, The Third Affiliated Hospital of Zhengzhou University, China
| | - Hua Ye
- The State Key Laboratory of Esophageal Cancer Prevention & Treatment, Zhengzhou University, China.,Department of Epidemiology and Health Statistics and Henan Key Laboratory of Tumor Epidemiology, College of Public Health, Zhengzhou University, China
| | - Guiying Sun
- The State Key Laboratory of Esophageal Cancer Prevention & Treatment, Zhengzhou University, China.,Department of Epidemiology and Health Statistics and Henan Key Laboratory of Tumor Epidemiology, College of Public Health, Zhengzhou University, China
| | - Keyan Wang
- The State Key Laboratory of Esophageal Cancer Prevention & Treatment, Zhengzhou University, China.,Henan Institute of Medical and Pharmaceutical Sciences, Zhengzhou University, China
| | - Liping Dai
- The State Key Laboratory of Esophageal Cancer Prevention & Treatment, Zhengzhou University, China.,Henan Institute of Medical and Pharmaceutical Sciences, Zhengzhou University, China
| | - Cuipeng Qiu
- The State Key Laboratory of Esophageal Cancer Prevention & Treatment, Zhengzhou University, China.,Department of Epidemiology and Health Statistics and Henan Key Laboratory of Tumor Epidemiology, College of Public Health, Zhengzhou University, China
| | - Jianxiang Shi
- The State Key Laboratory of Esophageal Cancer Prevention & Treatment, Zhengzhou University, China.,Henan Institute of Medical and Pharmaceutical Sciences, Zhengzhou University, China
| | - Jicun Zhu
- The State Key Laboratory of Esophageal Cancer Prevention & Treatment, Zhengzhou University, China.,Department of Epidemiology and Health Statistics and Henan Key Laboratory of Tumor Epidemiology, College of Public Health, Zhengzhou University, China
| | - Xiao Wang
- Henan Institute of Medical and Pharmaceutical Sciences, Zhengzhou University, China
| | - Peng Wang
- The State Key Laboratory of Esophageal Cancer Prevention & Treatment, Zhengzhou University, China.,Department of Epidemiology and Health Statistics and Henan Key Laboratory of Tumor Epidemiology, College of Public Health, Zhengzhou University, China
| |
Collapse
|
|
2
|
Clinical Observation of Helicobacter pylori Infection and Risk Factors and Cytotoxin-Associated Protein A in Patients with Coronary Heart Disease. CONTRAST MEDIA & MOLECULAR IMAGING 2022; 2022:6814140. [PMID: 36072635 PMCID: PMC9402355 DOI: 10.1155/2022/6814140] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 05/25/2022] [Revised: 07/09/2022] [Accepted: 07/18/2022] [Indexed: 11/25/2022]
Abstract
The aim was to analyze the infection, influencing factors, and clinical manifestations of Helicobacter pylori infection, coronary heart disease, and cytotoxin-associated protein A infection, so as to provide reference for the improvement of clinical diagnosis and treatment level of in-depth treatment. This paper presents a clinical observation method based on Helicobacter pylori infection, risk factors, and cytotoxin-associated protein A in patients with coronary heart disease. Methods. 237 patients with CHD diagnosed and tested by 14C breath test were selected from inpatients of cardiovascular diseases in a hospital for retrospective analysis. The clinical data, serum deepening indicators, Hcy, and other factors were analyzed through general condition investigation, previous history investigation, and physical examination. The patients were observed by the SPSS22.0 statistical data processing method. The results showed that among the respondents, 175 cases were HP-positive, the infection rate was 73.8%, 77 patients with stable angina pectoris were 64.9%, and 160 patients with acute coronary heart disease were 78.1%. The difference between the groups was statistically significant (P < 0.05). Conclusion. Helicobacter pylori cytotoxic-associated protein A can increase the risk of gastric cancer, and Helicobacter pylori eradication treatment is more conducive to reduce the incidence of gastric cancer and ensure the safety of patients.
Collapse
|